Acta Neurologica Scandinavica · 1989 · 15 citations · 17 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsAcute Stroke ManagementCerebrovascular DiseaseStrokeStroke Prevention PharmacotherapyPost-stroke Antithrombotic TherapyRecurrent Stroke PreventionStroke Recurrence PreventionTransient Ischemic Attack Prevention
Out of 235 patients with recent cerebral transient ischaemic attacks, 208 subjects were available for final evaluation after 6 months' randomised treatment with either pentoxifylline (PTX 1200 mg/day) or a combination (ASAD) of acetylsalicylic acid (ASA, 1050 mg/day) and dipyridamole (D, 150 mg/day). Prevention of TIA, stroke or death attributable to previous events were endpoint criteria. The pentoxifylline group (n = 100) exhibited no recurrent episodes in 86 patients (86%). TIA occurred in 9 patients, stroke in 5 patients and there was 1 death. In the ASAD group (n = 108) no recurrence of ischaemic episodes was recorded in 82 cases (75.9%). TIA occurred in 20 patients, stroke in 6 patients and there were 3 deaths of vascular origin. Side effects were recorded in 4 ASAD and 1 PTX patients. The total rate of recurrence was 14% with PTX as compared to 24.1% with ASAD treatment.
17
Controlled trial of aspirin in cerebral ischemia.
William S. Fields, Noreen A. Lemak, Ralph F. Frankowski et al. · Stroke · 1977 · 634 citations · Full text
Medicine, Neurology, Pharmacotherapy +17
Whole blood viscosity parameters and cerebral blood flow.
James C. Grotta, Robert H. Ackerman, John A. Correia et al. · Stroke · 1982 · 252 citations · Full text
Medicine, Neurology, Physiology +17
Antithrombotic Potential of Pentoxifylline A Hemorheologically Active Drug
Reiner H. Schröer · Angiology · 1985 · 85 citations
Medicine, Hematology, Pharmacology +17